Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ziemer

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|July 4, 2012
[Diagnostics and exclusion of hereditary angioedema : a standarized approach for the practice]M Magerl, J Brasch, U Förster, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 24, 2024
Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoidN Kramer, G Müller, S Zierold, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 27, 2024
Health-related quality of life and its influencing factors in patients with primary cutaneous B-cell lymphomas: A multicentric study in 100 patientsA E C Schirren, J D Albrecht, S Melchers, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2023
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trialE Livingstone, H Gogas, L Kandolf-Sekulovic, et al.
ESMO Open|May 9, 2025
Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trialE Livingstone, H J Gogas, L Kandolf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2025
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanomaK C Kähler, J C Hassel, M Ziemer, et al.
JAMA Dermatology|May 31, 2023
Development of a Skin-Directed Scoring System for Stevens-Johnson Syndrome and Epidermal Necrolysis: A Delphi Consensus ExerciseMargo Waters, Allison Dobry, Stephanie T Le, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|July 4, 2012
[Diagnostics and exclusion of hereditary angioedema : a standarized approach for the practice]M Magerl, J Brasch, U Förster, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 24, 2024
Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoidN Kramer, G Müller, S Zierold, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 27, 2024
Health-related quality of life and its influencing factors in patients with primary cutaneous B-cell lymphomas: A multicentric study in 100 patientsA E C Schirren, J D Albrecht, S Melchers, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2023
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trialE Livingstone, H Gogas, L Kandolf-Sekulovic, et al.
ESMO Open|May 9, 2025
Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trialE Livingstone, H J Gogas, L Kandolf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2025
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanomaK C Kähler, J C Hassel, M Ziemer, et al.
JAMA Dermatology|May 31, 2023
Development of a Skin-Directed Scoring System for Stevens-Johnson Syndrome and Epidermal Necrolysis: A Delphi Consensus ExerciseMargo Waters, Allison Dobry, Stephanie T Le, et al.
Pageof 7